Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shanghai CP Guojian Pharmaceutical Co.,Ltd.
ClinicalTrials.gov Identifier:
NCT01459887
First received: October 18, 2011
Last updated: October 25, 2011
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2011
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)